| Literature DB >> 30132391 |
Valeria Savasi1,2, Monica Oneta1, Arianna Laoreti1,2, Francesca Parisi1,2, Bina Parrilla1, Piergiorgio Duca3, Irene Cetin1,2.
Abstract
HIV-1-affected couples' desire to have children and free sexual intercourses with the use of pre-exposure prophylaxis for the negative partner has emerged as an alternative option to assisted reproduction in aviremic patients under highly active antiretroviral therapy (HAART). It is already known that sperm quality may be impaired in HIV-infected men. The underlying physiopathological mechanism is still debated. The aim of this study was to evaluate the effects of HAART on sperm DNA fragmentation, comparing HIV-1-infected patients taking HAART versus naïve HIV-1-infected patients. This is a prospective case-control study. Sperm nuclear DNA fragmentation rate was evaluated by the sperm chromatin dispersion test in 77 HIV-infected men: 53 HIV-1 patients receiving HAART (Group 1) versus 24 naïve HIV-1 patients not receiving HAART (Group 2). Complete semen analysis was performed according to WHO 2010 recommendations. Patients with HBV infection or HCV infection coinfections and genital tract infections wre excluded. All the patients did not present any clinical signs of their disease. Seminal parameters were examined in the two groups, showing no significant differences. Increased sperm DNA fragmentation > 30% was demonstrated in 67.9% of patients in Group 1 and 37.5% of patients in Group 2, respectively ( p = .02). A positive but nonsignificant trend toward increased fragmentation was reported with advancing patients' age. In conclusion, sperm nuclear fragmentation rate is increased in HIV-1-infected patients taking HAART compared to HIV-1 patients not receiving HAART.Entities:
Keywords: HIV/AIDS; male family planning; male infertility; physiological and endocrine disorders; sexuality; sexually transmitted diseases/infections
Mesh:
Year: 2018 PMID: 30132391 PMCID: PMC6199444 DOI: 10.1177/1557988318794282
Source DB: PubMed Journal: Am J Mens Health ISSN: 1557-9883
Population Characteristics.
| Group 1 - HAART | Group 2 - NAÏVE | ||
|---|---|---|---|
| Age (years); median (range) | 42 (28–54) | 39 (25–49) | NS |
| Duration of HIV-1 infection (years); median (range) | 14 (3–32) | 5 (1–27) | NS |
| Time under HAART (years); median (range) | 8 (1–14) | – | |
| CD4 count (cells/ml); median (range) | 470 (71–1670) | 445 (149–1086) | NS |
| Undetectable viral load, | 53 (100%) | 24 (100%) | |
|
| |||
| High school, | 24 (45.3) | 12 (50) | NS |
| University, | 5 (9.4) | 3 (12.5) | NS |
| Unknown, | 24 (45.3) | 9 (37.5) | NS |
| Employed, | 48 (90.6) | 21 (87.5) | NS |
|
| |||
| Injection drugs, | 2 (4%) | 1 (4%) | NS |
| Sexual transmission, | 31 (58%) | 21 (88%) | NS |
| Blood product transmission, | 20 (38%) | 2 (8%) | NS |
Note. The comparison between groups was performed using χ2 or exact tests for categorical variables and Mann–Whitney U test for continuous variables. Statistically significant difference as p < .05. HAART = highly-active antiretroviral therapy; NS = not significant.
Different Seminal Parameters in Group 1 (HAART) Versus Group 2 (NAÏVE).
| Group 1 - HAART | Group 2 - NAÏVE | OR (95% CI) | ||
|---|---|---|---|---|
| Patients with ejaculate volume <1.5 ml, | 7 (13.2) | 1 (4.2) | .21 | 3.7 [0.42, 31.6] |
| Patients with concentration of spermatozoa < 39 × 106 /ejaculate, | 25 (47.2) | 16 (66.7) | .11 | 0.4 [0.16, 1.2] |
| Patients with progressive motility < 40%, | 20 (37.7) | 10 (41.7) | .71 | 0.8 [0.31, 2.2] |
| Patients with abnormal morphology < 4%, | 4 (7.5) | 5 (20.8) | .09 | 0.3 [0.07, 1.3] |
Note. The comparison between groups was performed using χ2 test.
Semen Fragmentation, Motility, and Sperm Cells after Capacitation in Group 1 (HAART) Versus Group 2 (NAÏVE).
| Group 1 - HAART | Group 2 - NAÏVE | ||
|---|---|---|---|
| Fragmentation (DFI %); Median (range) | 39 (13–78) | 22.5 (8–66) | .0001 |
| Motility a + b (%); Median (range) | 43 (10–73) | 45 (13–58) | .67 |
| Sperm cells after capacitation, (Million /0,5); Median (range) | 4 (0.1–20) | 3 (0.025–14) | .64 |
Note. The comparison between groups was performed using Mann–Whitney U test.
DFI = DNA fragmentation index (%).
Figure 1.Differences in semen parameters in Group receiving HAART therapy versus naive Group. Fragmentation index (DFI%) is significantly highest in HAART group compared to naive one.
Comparison of Sperm DNA Fragmentation in Group 1 (HAART) Versus Group 2 (NAÏVE) According to Age.
| Sperm DNA Fragmentation > 30% | Group 1- HAART | Group 2 - NAÏVE |
|---|---|---|
| Age 25−38 years | 10/15 (66.7%) | 5/13 (38.5%) |
| Age 39−43 years | 11/17 (64.7%) | 3/7 (42.9%) |
| Age 44−54 years | 15/21 (71.4%) | 1/4 (25%) |
|
|
|
|
Note. OR (Mantel–Haenszel): 3.51, p = .02, 95% CI [1.22, 10.12].
Figure 2.Differences in semen fragmentation index in three therapeutic regimens.
NRTI: Nucloside Reverse transcriptase inhibitor; NRTI + efavirenz; NRTI + IP (Protease inhibitor).